

Dear Shareholders, Health Care Providers, Partners, Patients and Employees,

As you can imagine we continue to carefully oversee the rapidly unfolding global COVID-19 situation. We are monitoring the situation day-by-day to ensure, first and foremost, patient and employee safety.

For our clinical trials we continue to be in close communication with our CRO and clinical sites – in many cases on a daily basis to ensure patient safety and business continuity through this difficult period.

Similarly, we are taking appropriate steps to protect our employees, their families and communities, including limitation of nonessential travel and leveraging technology resources to increase “social distancing”.

As for potential supply chain impact, last year, in anticipation of possible tariff escalation, we undertook a complete and thorough evaluation of our entire supply chain and took additional steps to ensure continued supply of key materials. As a result, with the current crisis, we believe we are in an advantageous position regarding our global supply chain.

As of now, we do not see any change in our overall program timelines. However, the situation is extremely fluid and may change at any time. If we do see any material impact as a result of COVID-19 we will take the necessary steps to inform you.

Please feel free to contact us at ir@arenapharm.com if you require additional information.

And please stay safe.

Amit D. Munshi
President and CEO
Arena Pharmaceuticals, Inc.

Date Posted: March 13, 2020

The COVID-19 (novel coronavirus) situation is rapidly evolving, and this update is based on information currently available to us. Statements we make that are forward-looking may involve risks and uncertainties as disclosed in our filings with the SEC, including the risk that the continuing spread of the coronavirus could significantly disrupt our operations or those of our collaborators, contractors and vendors, or contribute to unfavorable economic or other conditions that could adversely impact us. Actual results may differ materially from those stated or implied by our forward-looking statements, and we disclaim any intent or obligation to update forward-looking statements except as required under applicable law.